Robert Clarke, PhD, DsC

Robert Clarke, PhD, Dsc, is an internationally recognized leader in breast cancer research. Clarke studies how hormones, growth factors, and other related molecules affect breast cancer, and how breast cancers become resistant to hormonal and cytoxic chemotherapies. He has expertise in the fields of estrogens, antiestrogens, aromataseinhibitors, cell signaling, drug resistance, bioinformatics, and signal transduction.

Dr. Clarke has developed a series of hormone resistant breast cancer models that are now widely used in the field, and he continues to develop new experimental models. He is currently working on the development and application of genomic and novel iconoclastic methods to data from ongoing translation al studies in both humans and experimental models. In other research, Dr. Clarke and his colleagues have recently identified a new molecular signaling network in breast cancer that involves several novel oncogenes and suppressor genes. This integrated network incorporates cell stress signaling, protein misfolding, and communication amount the endoplasmic reticulum, mitochondria and nucleus of breast cancer cells. ultimately, this network determines if a breast cancer cell will grow, differentiate or die, and the mechanism by which the cell will die (apoptosis, autophagy, necrosis, senscence), in response to therapy.

Currently, Dr. Clarke leads several multinational molecular medicine studies in breast cancer, in collaboration with Dr. Minetta Liu (Lombardi) and colleagues at Virginia Tech and the University of Edinburgh (Scotland). With Dr. Subha Madhavan at Lombardi, he leads an NCI-funded InSilico Research Center of Excellence. Dr. Clarke also leads the caBIG team at the Georgetown Lombardi Comprehensive Cancer Center and he is regularly invited to speak about his research at international and national meetings. He serves on the editorial boards of over a dozen international peer review journals such as the Journal for Cancer Research and Endocrine-Related Cancer and is a member of the Editorial Boards of Clinical Cancer Research, Molecular Cancer Therapeutics, Cancer Prevention Research, Breast Cancer Research and Treatment, and the British Journal of Cancer.

Dr. Clarke currently serves as the Interim Director for the Biomedical Graduate Research Organization at Georgetown University Medical Center, home to 60% of biomedical research at GUMC. He is an Associate Vice President of GUMC, co-director of the Breast Cancer Program at Georgetown Lombardi Comprehensive Cancer Center and a member of the Georgetown University Faculty Senate.